Intellia’s gene editing breakthrough is historic
Head of Equity Strategy
Summary: Intellia Therapeutics' share price rose 50% yesterday as the biotechnology company showed promising results against a rare genetic liver disease. The gene editing technology is one of the most promising technology within disease treatments and the key to unlock the full potential of adaptive cell therapies.
Back in January we launched our NextGen Medicine theme basket consisting of 30 companies within what we call the frontier of biotechnology. There is the mature biotechnology industry, which is closer to the old pharmaceutical industry, and then there is this new frontier of biotechnology companies working antibody therapies, gene editing, T-cell therapy, immunology, mRNA technology and genetic diagnostics.
Over the weekend, Intellia Therapeutics and Regeneron Pharmaceuticals (part of the mature biotechnology industry) released a landmark phase 1 clinical data showing significant reduction in disease-causing protein following CRISPR therapy for Transthyretin (ATTR) Amyloidosis. Experts have called this a major breakthrough for the promising gene editing technology CRISPR, pioneered by the two female scientists Charpentier and Doudna which won them the Nobel Prize in Chemistry, which is necessary to increase the potential of adoptive cell therapy (ACT). The news lifted Intellia’s share price by 50% yesterday and our NextGen Medicine basket by 3.9% showing how Intellia’s result is lifting the outlook for many of these new emerging biotechnology companies within these new technologies.
The table below shows the 30 companies in our NextGen Medicine basket and provide a broad-based exposure to this part of the biotechnology industry. It is our expectation that the biggest breakthroughs in medicine over the coming decades will come from this part of industry. Some of the other gene editing companies in the list are CRISPR Therapeutics, Beam Therapeutics, Editas Medicine and PTC Therapeutics.
|Name||Domicile||Mkt cap in USD mn||R&D in %||12M Rev in USD mn||Burn rate||Insti %|
|Exact Sciences Corp||US||22,475||2.8||1,546||NM||102.3|
|CRISPR Therapeutics AG (**)||CH||11,489||2.6||1||5.5||70.5|
|Mirati Therapeutics Inc||US||8,861||3.7||13||4.2||114.9|
|Fate Therapeutics Inc||US||8,380||1.5||40||10.2||110.2|
|Ultragenyx Pharmaceutical Inc||US||6,505||6.9||334||2.9||132.2|
|Twist Bioscience Corp||US||6,177||0.8||113||2.5||126.1|
|Denali Therapeutics Inc||US||9,095||2.4||340||NM||102.1|
|Arrowhead Pharmaceuticals Inc||US||8,974||1.8||89||NM||74.1|
|Iovance Biotherapeutics Inc||US||4,116||4.9||0||2.4||127.3|
|Pacific Biosciences of California Inc||US||7,010||1.0||92||4.0||91.8|
|Beam Therapeutics Inc||US||6,812||4.0||0||2.3||106.8|
|Swedish Orphan Biovitrum AB||SE||5,533||3.5||1,612||NM||107.9|
|Sage Therapeutics Inc||US||3,345||8.6||1,113||NM||119.8|
|Intellia Therapeutics Inc||US||9,094||1.7||52||8.7||109.3|
|Editas Medicine Inc||US||2,988||5.5||92||2.2||87.1|
|PTC Therapeutics Inc||US||3,067||17.0||430||4.8||124.2|
|Allogene Therapeutics Inc||US||3,616||5.7||38||4.5||125.7|
Source: Bloomberg and Saxo Group
Table explanations: R&D in % is the 12-month R&D expense in % of market cap, Burn rate is the number of years the company can sustain current negative free cash flow (NM means not measurable and is used for those with positive free cash flow), Insti % is the institutional ownership of the floating shares (those that are tradeable, so if all shares are not publicly available then the ratio can be above 100%) in %.
** Peter Garnry has holdings in these companies
Latest Market Insights
Outrageous Predictions 2023: The War Economy
- The constantly growing global need for energy drives the world's richest to huddle up and launch a R&D project in a size the world hasn't seen since the Manhattan Project gave the US the first atomic bomb.
French President Macron resignsThe political stalemate in France and the rise of Marie Le Pen following the 2022 elections corners President Macron, forcing him to give up on politics and resign from his position. At least for now.
Gold rockets to USD 3,000 as central banks fail on inflation mandateAs markets and central banks realise that the idea that inflation is transitory is wrong, and that prices will remain higher for longer, gold is sent through the roof, hitting a price tag of USD 3,000
EU Army forces EU down path to full unionWith continued challenges in the region and a US military that isn't aggressively enacting its former role as global policeman, the European Union agrees to create its own armed forces, bringing the whole region closer.
A country agrees to ban all meat production by 2030In an effort to become one of the global leaders on the path to net-zero emissions, one country decides to not only put a heavy tax on meat, but to ban domestic production entirely.
UK holds UnBrexit referendumFollowing a recession and domestic pressure, the United Kingdom is thrown into political turmoil that will end with a vote to wind back Brexit.
Widespread price controls are introduced to cap official inflationHistory tells us that with the war economy comes rationing and price controls. And this time is no different, as policymakers introduce strict price controls that lead to a range of unintended consequences.
OPEC+ & Chindia walk out of the IMF, agree to trade with new reserve assetSanctions against Russia have caused widespread turmoil due to US Dollar moves in countries across the globe that don't consider the US an ally. To relieve themselves from this, they leave the IMF and create a new reserve asset.
USDJPY fixed to the USD at 200 as Japan overhauls financial systemFollowing the challenges that faced the Japanese Yen in 2022, the Bank of Japan attempts to keep the currency from sliding. Unsuccessful on the long-term, Japan will launch a reset of its entire financial system.
Tax haven ban kills private equityWith the war economy comes an increased focus on national interests and sovereign nations' ability to assert themselves. In that regard, the OECD countries turn their attention on tax havens and pull the big guns out, banning them altogether.